Syngene posted its financials for the third quarter on 22 January, with revenue and profit missing estimates.(AFP) Contract drug research and manufacturing firm Syngene International Ltd has lowered ...

From its September highs of Rs 860.25, the stock has corrected more than 15 percent. Syngene shares slipped three percent in early trade on January 16 after UBS downgraded the counter to ‘sell’ from ...

Protean eGov Technologies shares plunge to a new 52-week low after missing out on the PAN 2.0 project bid (Image: Shutterstock) Syngene International’s share price tanked 13.22% to an intra-day low of ...

Monoclonal antibodies (mAbs) have revolutionized modern medicine, offering precision therapies for cancer, autoimmune disorders, infectious diseases, and numerous other advantages. The global mAb ...

Shares of Syngene International Ltd tumbled 10 per cent in Thursday's trade after the company gave a muted revenue guidance for FY26. Post Q4 results, Managing Director and CEO at Syngene ...

Syngene International adapts to industry challenges, focusing on balanced growth in R&D and manufacturing. Biologics are a key growth driver for Syngene, with expanded capabilities for discovery and ...

Bengaluru: Biocon’s subsidiary Syngene has acquired Unit 3’s biologics manufacturing facility in Bengaluru from Stelis Biopharma (SBL) for Rs 702 crore. On completion of the transaction, the site will ...

Syngene International has concluded the acquisition of its first biologics site in the US, which was announced on March 10, 2025. The state-of-the-art biologics facility, fitted with multiple ...